Portalak syrup 66.7% 250ml

Portalak user manual

Reed more and buy Portalak on this page

Portalak is a laxative drug that stimulates intestinal motility.

Release form and composition

The drug is produced in the form of a syrup: a viscous transparent liquid from colorless to brown-yellow colored (200, 250, 480, 500 and 1000 ml in plastic bottles, in a cardboard pack 1 bottle complete with a measuring cup and instructions for use of Portalak) .
100 ml of syrup contains:
    active substance: lactulose concentrate - 66.7 g;
    auxiliary component: purified water.

Pharmacodynamics

Portalak is a laxative with a hyperosmotic effect. Its mechanism of action is due to the influence of lactulose on the potentiation of the process of reproduction in the intestines of Lactobacillus acidophilus and Lactobacillus bifidus, which causes a decrease in acidity in the lumen of the large intestine and the activation of its peristalsis. Along with the stimulation of intestinal motility, lactulose helps to improve the absorption of phosphates and calcium salts, the excretion of ammonium ions, and slow the growth of salmonella in the large intestine. Against the background of taking Portalak, the amount of feces increases and their softening occurs. Syrup does not directly affect the mucous membrane and smooth muscles of the large intestine.
Exposure to lactulose helps to reduce the formation of nitrogen-containing toxic substances in the proximal colon and their absorption into the systemic circulation. The level of ammonium ion in the blood decreases by 25–50%, the severity of hepatic encephalopathy decreases, the patient’s mental state improves, and electroencephalography normalizes.
After taking the syrup inside, the therapeutic effect occurs as the drug passes through the gastrointestinal tract (GIT) for 24–48 hours.

Pharmacokinetics

After oral administration, lactulose is practically not absorbed from the digestive tract, no more than 3% of the dose is absorbed.
With the simultaneous intake of vitamins, their absorption does not decrease.
Portalak is not addictive.
Due to the insignificant systemic effect of lactulose for elderly patients, with renal or hepatic insufficiency, a dosage regimen correction is not required.

Indications for use

    constipation, including chronic form of constipation;
    intestinal dysbiosis;
    hemorrhoids, pain after removal of hemorrhoids, preparation for surgery on the colon and / or anus, postoperative period - with the aim of softening the stool for medical purposes;
    hyperammonemia;
    hepatic encephalopathy;
    treatment and prevention of hepatic precoma and coma;
    enteritis due to salmonella or shigella;
    salmonella carriage;
    putrefactive dyspepsia syndrome in young children due to acute food poisoning.

Contraindications

Absolute:
    bowel obstruction;
    galactosemia;
    rectal bleeding not associated with hemorrhoids;
    colostomy, ileostomy;
    suspected appendicitis;
    idiosyncrasy of lactulose.
With caution, Portalak should be taken to patients with lactose intolerance, diabetes mellitus, gastrocardial syndrome.

Instructions for use: method and dosage

The syrup is taken orally, preferably during or after a meal, washed down with water or another liquid.
The dose of the drug should be selected individually. Change the dose or time of administration as necessary.
After the start of administration, the laxative effect develops during the first two days of therapy.
Recommended dosage:
    treatment of constipation and softening of the stool: infants up to 1 year old - 5 ml (1 teaspoon) per day; children aged 1-6 years - 5-10 ml per day; children from 7 to 14 years old, the initial dose (3 days) - 15 ml (1 tablespoon) per day, the maintenance dose - 10 ml per day; adults, the initial dose is 15–45 ml per day for three days, then 15–30 ml per day. The daily dose is taken once in the morning or divided into two doses. In the treatment of constipation, the duration of the course can be from 28 to 120 days;
    treatment of hepatic (portal) encephalopathy, hepatic coma and precoma: 30-50 ml 3 times a day. In order to achieve a quick effect, the initial dose can be 30–45 ml with an interval of 1–2 hours. After the first bowel movement, the patient is transferred to a maintenance individual dose that provides soft stools 2-3 times a day;
    treatment of dysbiosis, normalization of intestinal microflora: a single dose for children up to 1 year old is 1.5–3 ml, from 1 to 3 years old - 3 ml, from 3 to 7 years old - 5 ml, for adults and children over 7 years old - 5– 10 ml It is divided into 2–4 doses per day during or after meals. The duration of treatment is 10-14 days. Repeated courses are prescribed with an interval of 7 days.

Side effects

Adverse events associated with the use of Portalak occur, as a rule, due to excess doses and are mild reversible. To reduce the feeling of discomfort or abdominal pain, cramping and diarrhea, a dose reduction is sufficient.
Flatulence that appears at the beginning of treatment usually disappears in 1-2 days.
Skin reactions in the form of a rash are possible.
Long-term use of high doses of lactulose in the treatment of hepatic encephalopathy can cause water-electrolyte imbalance in patients, resulting in weakness, increased fatigue, nausea, headache, dizziness, convulsions, arrhythmias, myalgia.

Overdose

Symptoms of an overdose of lactulose are diarrhea, a violation of the water-electrolyte balance.
In order to treat the condition, you should immediately stop taking the laxative.

Special instructions

If, after several days of taking Portalak, constipation persists, or if constipation resumes after discontinuation of the drug, consult your doctor.
Patients with lactose intolerance and patients with diabetes should note that 15 ml of syrup contains up to 1.7 g of galactose and up to 1 g of lactose.
Treatment of patients with gastrocardial syndrome should begin with reduced doses, then gradually increase them, this will minimize the risk of flatulence.
In the treatment of hepatic encephalopathy, other laxatives cannot be used simultaneously, especially in the initial phase of therapy. Intensive bowel movement may erroneously indicate the achievement of an adequate dose for the treatment of encephalopathy.

Influence on the ability to drive vehicles and complex mechanisms

The use of recommended doses of lactulose does not affect the ability of patients to drive vehicles and complex mechanisms.

Pregnancy and lactation

According to clinical indications, the use of Portalak during pregnancy and breastfeeding is allowed.

Use in childhood

The use of Portalak syrup in children of any age (from birth) is shown in accordance with the recommended dosage regimen.

Drug interaction

During the first two hours after taking any other medicine, it is recommended to refrain from taking Portalak.
When taken with drugs containing mesalazine, it should be borne in mind that the environment created by lactulose in the large intestine can contribute to their inactivation.
With concomitant antibiotic therapy (including neomycin) and antacids, the clinical effect of Portalak is reduced.

Terms and conditions of storage

Keep out of the reach of children.
Store at temperatures up to 25 ° C, do not allow freezing.
Shelf life is 3 years.

Reviews

Reviews about Portalak are positive. Patients indicate a high effectiveness of the drug in the treatment of constipation. It is especially noted that the laxative is approved for use by both adults and children (including infants and the elderly), as well as pregnant and lactating women. In addition, the advantages include a safe composition, pleasant taste, mild action, lack of addiction and the possibility of long-term use, good portability of Portalak.

Terms of sell

You can buy Portalak without a prescription.